AVDL: Avadel Pharmaceuticals Plc
About
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
Current Value
$10.711 Year Return
Current Value
$10.711 Year Return
Key Details
Market Cap
$1.03B
P/E Ratio
-13.88
1Y Stock Return
-3.16%
1Y Revenue Growth
1523.50%
Dividend Yield
0.00%
Price to Book
13.8
Strategies that include AVDL
Stock's related to AVDL
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LMND | 38.45% | $2.87B | +150.56% | 0.00% |
| ATEC | 38.38% | $1.36B | -16.49% | 0.00% |
| MGEE | 37.55% | $3.78B | +41.56% | 1.66% |
| SNDX | 36.59% | $1.35B | +2.87% | 0.00% |
| ROOT | 33.78% | $1.53B | +972.93% | 0.00% |
| CSV | 31.40% | $590.66M | +75.49% | 1.16% |
| NGNE | 30.59% | $223.88M | +32.95% | 0.00% |
| SXC | 29.97% | $1.05B | +39.93% | 3.52% |
| FLGT | 29.79% | $519.98M | -37.82% | 0.00% |
| RBLX | 28.69% | $34.28B | +42.27% | 0.00% |
| ITCI | 28.51% | $8.84B | +42.41% | 0.00% |
| MOGO | 28.46% | $36.95M | +26.89% | 0.00% |
| CRDF | 27.46% | $133.97M | +127.83% | 0.00% |
| GPRO | 27.22% | $179.52M | -67.23% | 0.00% |
| NRC | 26.88% | $442.05M | -55.00% | 2.56% |
| NNN | 26.59% | $8.14B | +10.88% | 5.30% |
| ARE | 26.49% | $18.26B | +0.69% | 4.97% |
| STC | 26.28% | $2.02B | +61.68% | 2.65% |
| KAR | 26.28% | $2.09B | +31.90% | 0.00% |
| FBIN | 26.27% | $9.14B | +11.58% | 1.29% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BTCT | -34.92% | $42.61M | +353.33% | 0.00% |
| PBT | -21.48% | $606.38M | -27.11% | 5.87% |
| MNOV | -19.99% | $93.19M | +2.15% | 0.00% |
| PULM | -19.86% | $19.83M | +202.98% | 0.00% |
| HII | -19.80% | $7.50B | -19.92% | 2.70% |
| ANIK | -16.02% | $249.56M | -17.52% | 0.00% |
| TCTM | -15.51% | $8.10M | -42.99% | 0.00% |
| LNG | -14.38% | $49.37B | +24.99% | 0.82% |
| STG | -14.25% | $35.67M | +7.92% | 0.00% |
| MVO | -14.17% | $106.15M | -22.78% | 16.78% |
| OXBR | -13.46% | $19.05M | +178.18% | 0.00% |
| VRN | -13.46% | $3.23B | -25.43% | 6.21% |
| TBRG | -12.75% | $244.47M | +52.66% | 0.00% |
| NNE | -12.55% | $833.66M | +531.50% | 0.00% |
| WSC | -12.26% | $6.49B | -7.82% | 0.00% |
| APTV | -12.22% | $12.25B | -35.53% | 0.00% |
| CHRW | -11.56% | $12.89B | +32.52% | 2.24% |
| AOUT | -11.47% | $118.33M | +9.76% | 0.00% |
| AXS | -11.39% | $7.14B | +55.12% | 2.06% |
| TSN | -11.23% | $21.95B | +31.14% | 3.11% |
ETF's related to AVDL
News
Yahoo
Avadel Pharmaceuticals ( NASDAQ:AVDL ) Third Quarter 2024 Results Key Financial Results Revenue: US$50.0m (up by...
Yahoo
DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20 at 7:30 a.m. GMT / 2:30 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com
Yahoo
Avadel Pharmaceuticals PLC (AVDL) reports robust Q3 performance with $50 million in net revenue and strategic expansions in patient care and market reach.
SeekingAlpha
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ETCompany ParticipantsAustin Murtagh - Director,...
Yahoo
DUBLIN (AP) — Avadel Pharmaceuticals PLC (AVDL) on Tuesday reported a loss of $2.6 million in its third quarter. The Dublin-based company said it had a loss of 3 cents per share. The results topped Wall Street expectations.
Yahoo
-- Generated $50.0 million in net revenue from sales of LUMRYZ™ -- --2,300 patients on LUMRYZ as of September 30th, including 700 patients that initiated therapy in the quarter -- -- Received FDA approval for LUMRYZ for the treatment of cataplexy or EDS in patients 7 years and older with narcolepsy, granted ODE through October 16, 2031 -- -- LUMRYZ approval upheld by court in suit brought by Jazz regarding FDA’s determination that LUMRYZ is clinically superior to twice-nightly oxybate products -
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.